Difference between revisions of "Cladribine (Leustatin)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
|||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
<br>Extravasation: [[irritant]] or [[neutral]], depending on reference | <br>Extravasation: [[irritant]] or [[neutral]], depending on reference | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is established ''(work in progress)''== | ==Diseases for which it is established ''(work in progress)''== | ||
*[[Mantle cell lymphoma]] | *[[Mantle cell lymphoma]] | ||
| Line 16: | Line 16: | ||
*[[Hypereosinophilic syndrome]] | *[[Hypereosinophilic syndrome]] | ||
*[[Langerhans cell histiocytosis]] | *[[Langerhans cell histiocytosis]] | ||
| − | |||
*[[Systemic mastocytosis]] | *[[Systemic mastocytosis]] | ||
*[[Waldenström macroglobulinemia]] | *[[Waldenström macroglobulinemia]] | ||
| Line 22: | Line 21: | ||
==Patient drug information== | ==Patient drug information== | ||
*[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a2592a9b-bca6-4a5a-89c2-855a0634d5fe Cladribine package insert]<ref name="insert"></ref> | *[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a2592a9b-bca6-4a5a-89c2-855a0634d5fe Cladribine package insert]<ref name="insert"></ref> | ||
| − | *[https://chemocare.com/ | + | *[https://chemocare.com/druginfo/cladribine.aspx Cladribine (Leustatin) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/cladribine.aspx Cladribine (Leustatin) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/cladribine-patient-drug-information Cladribine (Leustatin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cladribine-patient-drug-information Cladribine (Leustatin) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/cladribine-patient-drug-information Cladribine (Leustatin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cladribine-patient-drug-information Cladribine (Leustatin) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | * 1993-02-26: Initial FDA approval for treatment of active [[hairy cell leukemia]]. ''(Based on Saven et al. 1998)'' |
| − | + | ==History of changes in EMA indication== | |
| + | *1993-02-26: EURD | ||
==Also known as== | ==Also known as== | ||
*'''Generic names:''' 2-chlorodeoxyadenosine, 2-CdA | *'''Generic names:''' 2-chlorodeoxyadenosine, 2-CdA | ||
| Line 42: | Line 42: | ||
[[Category:Antimetabolites]] | [[Category:Antimetabolites]] | ||
| − | [[Category:Purine | + | [[Category:Purine analogs]] |
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
| Line 52: | Line 52: | ||
[[Category:MALT lymphoma medications]] | [[Category:MALT lymphoma medications]] | ||
[[Category:Mantle cell lymphoma medications]] | [[Category:Mantle cell lymphoma medications]] | ||
| − | |||
[[Category:Systemic mastocytosis medications]] | [[Category:Systemic mastocytosis medications]] | ||
[[Category:Waldenström macroglobulinemia medications]] | [[Category:Waldenström macroglobulinemia medications]] | ||
[[Category:FDA approved in 1993]] | [[Category:FDA approved in 1993]] | ||
| + | [[Category:EMA approved in 1993]] | ||
Latest revision as of 01:02, 29 June 2024
General information
Class/mechanism: Purine analog; mimics the nucleoside adenosine, inhibiting adenosine deaminase, which interferes with DNA synthesis and repair.[1][2]
Route: IV, SC
Extravasation: irritant or neutral, depending on reference
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Diseases for which it is established (work in progress)
Diseases for which it is used
- Acute myeloid leukemia
- B-cell lymphoma of mucosa-associated lymphoid tissue
- Chronic lymphocytic leukemia
- Follicular lymphoma
- Hairy cell leukemia
- Hypereosinophilic syndrome
- Langerhans cell histiocytosis
- Systemic mastocytosis
- Waldenström macroglobulinemia
Patient drug information
- Cladribine package insert[1]
- Cladribine (Leustatin) patient drug information (Chemocare)[3]
- Cladribine (Leustatin) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1993-02-26: Initial FDA approval for treatment of active hairy cell leukemia. (Based on Saven et al. 1998)
History of changes in EMA indication
- 1993-02-26: EURD
Also known as
- Generic names: 2-chlorodeoxyadenosine, 2-CdA
- Brand names: Leustatin, Litak, Movectro
References
Categories:
- Drugs
- Intravenous medications
- Subcutaneous medications
- Irritant
- Neutral
- Antimetabolites
- Purine analogs
- Acute myeloid leukemia medications
- Chronic lymphocytic leukemia medications
- Follicular lymphoma medications
- Hairy cell leukemia medications
- Hypereosinophilic syndrome medications
- Langerhans cell histiocytosis medications
- MALT lymphoma medications
- Mantle cell lymphoma medications
- Systemic mastocytosis medications
- Waldenström macroglobulinemia medications
- FDA approved in 1993
- EMA approved in 1993